Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jess W. Sager is active.

Publication


Featured researches published by Jess W. Sager.


Tetrahedron | 1997

Synthesis of the orally active spiroindoline-based growth hormone secretagogue, MK-677

Peter E. Maligres; Ioannis N. Houpis; Kai Rossen; Audrey Molina; Jess W. Sager; Veena Upadhyay; Kenneth M. Wells; Robert A. Reamer; Joseph E. Lynch; David Askin; Ralph P. Volante; Paul J. Reider; Peter G. Houghton

Abstract The preparation of the Merck Growth Hormone Secretagogue; MK-677 is described. A Fischer indole/reduction based strategy provides the novel spiroindoline nucleus of this potent compound. This optimized sequence necessitates the isolation of only one intermediate 10 and provides MK-677 in 48% overall yield from isonipecotic acid 3.


Tetrahedron | 1996

Cyclic imidate salts in acyclic stereochemistry: Diastereoselective syn-epoxidation of 2-alkyl-4-enamides to epoxyamides

Peter E. Maligres; Steven A. Weissman; Veena Upadhyay; Steven J. Cianciosi; Robert A. Reamer; Robert Purick; Jess W. Sager; Kai Rossen; Kan K. Eng; David Askin; Ralph P. Volante; Paul J. Reider

Abstract Reaction of 2-alkyl-4-enamides with 1 + and aqueous sodium bicarbonate results in the diastereoselective formation of the corresponding iodohydrins with essentially no iodolactone by-product. The reaction appears to proceed through a cyclic imidate type intermediate. This methodology has been successfully employed for the synthesis of the epoxide intermediate of the orally active HIV-1 protease inhibitor MK-639 (indinavir sulfate).


Tetrahedron | 1999

Crystallization-induced asymmetric transformation: Stereospecific synthesis of L-768,673

Yao-Jun Shi; Kenneth M. Wells; Philip J. Pye; Woo-Baeg Choi; Hywyn R.O. Churchill; Joseph E. Lynch; Ashok Maliakal; Jess W. Sager; Kai Rossen; Ralph P. Volante; Paul J. Reider

Abstract A highly convergent, asymmetric synthesis of L-768,673, an I ks Class III antiarrythmic drug candidate, is described. Synthesis of the recemic 1-trifluoroethyl-3-amino-5-phenyl benzodiazepinone [(±)-amine] was achieved by Ru-catalyzed hydrogenation of the corresponding oxime that was derived from commercially available 1-trifluoroethyl-5-phenyl benzodiazepine in 76% overall yield. An efficient one-pot resolution-racemization of (±)-amine provided the desired (±)-amine as its mandelate salt in 92% yield and 99.4% ee. Regioselective ortho-lithiation of 1,3-bis(trifluoromethyl)benzene with n-BuLi in the presence of a catalytic amount of 2,2′,6,6′-tetramethylpiperidine afforded its aryl lithium. Subsequent transmetalation and alkylation with allyl bromide produced the corresponding olefin. Ru-catalyzed oxidative cleavage of the terminated double bond of the olefin provided the desired 2,4-bis(trifluoromethyl)phenylacetic acid in 35% overall yield. A modified Schotten-Baumman procedure was developed for coupling of (+)-amine and the acid to produce L-768,673 in 92% yield without racemization.


Tetrahedron-asymmetry | 1997

The enantioselective synthesis of LTD4 antagonist L-708,738

Daniel R. Sidler; Jess W. Sager; James J. Bergan; Kenneth M. Wells; Mahadevan Bhupathy; Ralph P. Volante

Abstract An efficient, 9-step synthesis of LTD 4 antagonist L-708,738 is described. The asymmetric center is set via a chiral borane reduction.


Chemical Communications | 1998

Observation and quantification of a chiral medium induced difference in rate of enantiomerization

Kai Rossen; Jess W. Sager; Yongkui Sun

A chiral stationary phase HPLC column has been used both to separate the enantiomers of a γ-lactol and also to observe the rate of enantiomerization of the individual enantiomers; the rate of enantiomerization differed for both enantiomers in the presence of the chiral stationary phase.


Journal of Organic Chemistry | 2003

Highly regioselective Friedländer annulations with unmodified ketones employing novel amine catalysts: Syntheses of 2-substituted quinolines, 1,8-naphthyridines, and related heterocycles

Peter G. Dormer; Kan K. Eng; Roger N. Farr; Guy R. Humphrey; J. Christopher McWilliams; Paul J. Reider; Jess W. Sager; Ralph P. Volante


Archive | 1998

Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors

Philip J. Pye; Ashok Maliakal; Kai Rossen; Ralph P. Volante; Jess W. Sager


Journal of Heterocyclic Chemistry | 1995

A practical synthesis of 5-(chloromethyl)furo[2,3-b]pyridine, a key intermediate for the HIV protease inhibitor, L-754,394

M. Bhupathy; David A. Conlon; Kenneth M. Wells; John R. Nelson; Paul J. Reider; Kai Rossen; Jess W. Sager; Ralph P. Volante; Bruce D. Dorsey; Jacob M. Hoffman; Sally A. Joseph; Stacey L. McDaniel


Archive | 1996

Process for the preparation of spiroindolines

David Askin; Peter E. Maligres; Paul J. Reider; Kai Rossen; Jess W. Sager; Veena Upadhyay; Ralph P. Volante; Kenneth M. Wells


Archive | 2001

PROCESS FOR PREPARATION OF INTEGRIN RECEPTOR ANTAGONIST INTERMEDIATES

James Christopher Mcwilliams; Elizabeth Buck; Kan K. Eng; Guy R. Humphrey; Peter E. Maligres; Jess W. Sager; Marjorie S. Waters

Collaboration


Dive into the Jess W. Sager's collaboration.

Researchain Logo
Decentralizing Knowledge